We have characterized the antibody-antigen binding events of the prion protein (PrP) utilizing three new PrP-specific monoclonal antibodies (Mabs). The degree of immunoreactivity was dependent on the denaturation treatment with the combination of heat and SDS resulting in the highest levels of epitope accessibility and antibody binding. Interestingly however, this harsh denaturation treatment was not sufficient to completely and irreversibly abolish protein conformation. The Mabs differed in their PrP epitopes with Mab 08-1/11F12 binding in the region of PrP 93-122 , Mab 08-1/8E9 reacting to PrP and Mab 08-1/5D6 directed to an undefined conformational epitope. Using normal and infected brains from hamsters, sheep and deer, we demonstrate that the binding of PrP to one Mab triggers PrP epitope unmasking, which enhances the binding of a second Mab. This phenomenon, termed positive immunocooperativity, is specific regarding epitope and the sequence of binding events. Positive immunocooperativity will likely increase immunoassay sensitivity since assay conditions for PrP Sc detection does not require protease digestion.
Introduction
Prion diseases, also known as transmissible spongiform encephalopathies (TSEs), are invariably fatal neurodegenerative disorders affecting a broad spectrum of host species and arise via genetic, infectious, or sporadic mechanisms. In humans, prion diseases consist of various forms of Creutzfeldt-Jakob disease (sporadic, familial, iatrogenic, variant), Gerstmann-Straussler-Scheinker syndrome, Kuru and Fatal Familial Insomnia. Prion diseases in animals include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and chronic wasting disease (CWD) in deer and elk. (Glatzel et al., 2003; Collins et al., 2004; Prusiner, 1998; Abid and Soto, 2006; Wadsworth and Collinge, 2007) .
Regardless of the data supporting or refuting the prion (Prusiner, 1982), virino (Dickinson and Outram, 1988) and virus (for review see Manuelidis, 2007) theories of the nature of the infectious agent, a key event in prion diseases is the accumulation of an abnormal isoform (PrP Sc ) of a host-encoded protein, termed prion protein (PrP C ), predominantly in the nervous system of the infected host (Stahl et al., 1993) . Structurally, PrP consists of a disordered, flexible amino terminal region comprising approximately residues 23-124 and a globular carboxyl terminal domain (approximately residues 125-231).
The carboxyl terminal region is directly associated with the formation of fibrils and aggregates associated with the disease. The amino terminal region is involved in protein structural stability and the folding of PrP C to PrP Sc (Cordeiro et al., 2005) . PrP C and PrP Sc differ in their sensitivities to proteinase K (PK) with PrP C being completely digested and PrP Sc converted to a protease-resistant core (PrP27-30) comprising approximately the PrP residues 90-231. PrP C and PrP Sc also differ in their secondary and tertiary structures (Basler et al., 1986; Caughey et al., 1991; Stahl and Prusiner, 1991; Caughey and Raymond, 1991; Pan et al., 1993; Kocisko et al., 1994; 1995) . Fourier transform infrared and circular dichroism spectroscopy studies indicate that PrP C is highly helical (42%) with little ß-sheet structure (3%) (Pan et al., 1993) . In contrast, PrP Sc contains less helical structure (30%) and a large amount of ß-structure (43%). PrP C can be converted to the lethal PrP Sc conformation on contact with PrP Sc (Horiuchi and Caughey, 1999; Safar et al., 1998; Caughey, 2001 
